Bank of New York Mellon’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Bank of New York Mellon’s Portfolio ODT Stock Details ODT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-14,886	Closed	-$44K	–	4680
2021 Q3	$44K	Sell	14,886 -12,345	-45%	-$41K	﹤0.01%	4450
2021 Q2	$95K	Sell	27,231 -37,864	-58%	-$130K	﹤0.01%	4227
2021 Q1	$222K	Sell	65,095 -5,225	-7%	-$98.8K	﹤0.01%	4019
2020 Q4	$1.35M	Buy	70,320 +17,363	+33%	+$268K	﹤0.01%	3076
2020 Q3	$711K	Sell	52,957 -855	-2%	-$24.2K	﹤0.01%	3312
2020 Q2	$2.28M	Buy	53,812 +6,073	+13%	+$197K	﹤0.01%	2601
2020 Q1	$1.32M	Sell	47,739 -2,171	-4%	-$63.3K	﹤0.01%	2784
2019 Q4	$1.62M	Buy	49,910 +6,598	+15%	+$205K	﹤0.01%	2951
2019 Q3	$1.13M	Buy	43,312 +12,633	+41%	+$423K	﹤0.01%	3108
2019 Q2	$1.13M	Buy	30,679 +7,608	+33%	+$182K	﹤0.01%	3131
2019 Q1	$510K	Sell	23,071 -431	-2%	-$7.54K	﹤0.01%	3542
2018 Q4	$331K	Sell	23,502 -60,839	-72%	-$947K	﹤0.01%	3670
2018 Q3	$1.64M	Buy	84,341 +2,915	+4%	+$59.4K	﹤0.01%	2971
2018 Q2	$1.8M	Buy	81,426 +64,310	+376%	+$1.5M	﹤0.01%	2914
2018 Q1	$363K	Buy	+17,116	New	+$404K	﹤0.01%	3722

Other funds holding ODT

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MYDA Advisors Woodmere, New York $608M AUM 77.08% 1-Year Est. Return

Bank of New York Mellon's ODT Position: Q4 2021 in Review

Bank of New York Mellon sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q4 2021, closing a stake of 14,886 shares — an estimated $44K sold.

Bank of New York Mellon first reported a position in ODT in Q1 2018 and held it in 15 quarters. The position peaked at $2.28M in Q2 2020. 50 funds tracked by Wall St. Rank hold ODT as of Q4 2021.

Bank of New York Mellon reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
Bank of New York Mellon sold 14,886 Odonate Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $44K.
Bank of New York Mellon first reported a position in Odonate Therapeutics, Inc. Common Stock in Q1 2018 and held it in 15 quarters.
Bank of New York Mellon's Odonate Therapeutics, Inc. Common Stock position peaked at $2.28M in Q2 2020.
50 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Bank of New York Mellon's 13F filing for Q4 2021, filed 11 Feb 2022.